EUR 0.44
(0.0%)
Year | Operating Income | Operating Income Growth |
---|---|---|
2023 | -11.8 Million EUR | -39.49% |
2022 | -9.27 Million EUR | -5.54% |
2021 | -8.78 Million EUR | 0.96% |
2020 | -8.86 Million EUR | 34.85% |
2019 | -13.61 Million EUR | 0.0% |
Year | Operating Income | Operating Income Growth |
---|---|---|
2024 Q2 | -2.17 Million EUR | 0.0% |
2024 Q1 | -2.17 Million EUR | 39.69% |
2023 Q4 | -3.6 Million EUR | 0.0% |
2023 FY | -12.93 Million EUR | -39.49% |
2023 Q3 | -3.6 Million EUR | -57.03% |
2023 Q2 | -2.29 Million EUR | 0.0% |
2023 Q1 | -2.29 Million EUR | -8.4% |
2022 FY | -9.27 Million EUR | -5.54% |
2022 Q4 | -2.11 Million EUR | 0.0% |
2021 FY | -8.78 Million EUR | 0.96% |
2020 FY | -8.86 Million EUR | 34.85% |
2019 FY | -13.61 Million EUR | 0.0% |
Name | Operating Income | Operating Income Difference |
---|---|---|
Nicox S.A. | -17.5 Million EUR | 32.537% |
European Medical Solutions | -135 Thousand EUR | -8646.667% |
argenx SE | -417.15 Million EUR | 97.169% |
BioSenic S.A. | -7.04 Million EUR | -67.727% |
Celyad Oncology SA | -8.45 Million EUR | -39.624% |
Hyloris Pharmaceuticals SA | -15.99 Million EUR | 26.168% |
Onward Medical N.V. | -35.46 Million EUR | 66.703% |
Oxurion NV | -12.11 Million EUR | 2.494% |
PHAXIAM Therapeutics S.A. | -23.66 Million EUR | 50.093% |
Financière de Tubize SA | -2.14 Million EUR | -450.753% |
UCB SA | 604 Million EUR | 101.955% |